These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33771587)

  • 1. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
    Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
    Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
    Li Z; Zhou Z; Zhang L
    Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
    [No Abstract]   [Full Text] [Related]  

  • 4. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
    Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
    Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
    Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
    Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
    Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARĪ³/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics.
    Atanasio S; Deganutti G; Reynolds CA
    J Comput Aided Mol Des; 2020 Nov; 34(11):1181-1193. PubMed ID: 32851580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of a novel free fatty acid receptor 1 (FFAR1) agonist peptide by phage display and machine learning based-amino acid substitution.
    Yoshioka K; Yamashita H; Shimizu K; Shimomura S; Shibata T; Miyazaki JI; Honda H
    Biochem Biophys Res Commun; 2021 Apr; 550():177-183. PubMed ID: 33706101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.
    Lin DC; Guo Q; Luo J; Zhang J; Nguyen K; Chen M; Tran T; Dransfield PJ; Brown SP; Houze J; Vimolratana M; Jiao XY; Wang Y; Birdsall NJ; Swaminath G
    Mol Pharmacol; 2012 Nov; 82(5):843-59. PubMed ID: 22859723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening.
    Tikhonova IG; Sum CS; Neumann S; Engel S; Raaka BM; Costanzi S; Gershengorn MC
    J Med Chem; 2008 Feb; 51(3):625-33. PubMed ID: 18193825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An updated patent review of GPR40/ FFAR1 modulators (2020 - present).
    Ren Q; Fan Y; Yang L; Shan M; Shi W; Qian H
    Expert Opin Ther Pat; 2023; 33(9):565-577. PubMed ID: 37947382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
    Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.